Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 3/20 | 0.46 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.46 |
| ▸ | ATXN2 | Q99700 | 3/20 | 0.40 |
| ▸ | LIPE | Q05469 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | MAPK7 | Q13164 | 4/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17310935 | 0.88 | ENPP2 (0.53) | ENPP2DGAT2ATXN2LIPEHSD11B1 | |
| SCHEMBL16963420 | 0.88 | ENPP2 (0.53) | ENPP2DGAT2ATXN2LIPEHSD11B1 | |
| SCHEMBL17310934 | 0.88 | ENPP2 (0.53) | ENPP2DGAT2ATXN2LIPEHSD11B1 | |
| SCHEMBL16963795 | 0.87 | ENPP2 (0.42) | ENPP2DGAT2ATXN2LIPEHSD11B1 | |
| SCHEMBL16962688 | 0.85 | ENPP2 (0.49) | ENPP2DGAT2ATXN2LIPEMAPK7 | |
| SCHEMBL21323020 | 0.85 | ENPP2 (0.49) | ENPP2DGAT2ATXN2LIPEMAPK7 | |
| SCHEMBL16962689 | 0.85 | ENPP2 (0.49) | ENPP2DGAT2ATXN2LIPEMAPK7 | |
| SCHEMBL21323239 | 0.85 | ENPP2 (0.49) | ENPP2DGAT2ATXN2MGLL | |
| SCHEMBL16963314 | 0.85 | ENPP2 (0.49) | ENPP2DGAT2ATXN2MGLL | |
| SCHEMBL16963317 | 0.85 | ENPP2 (0.49) | ENPP2DGAT2ATXN2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669268-B2 | Bicyclic derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20180118741-A1 | NEW BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118741-A1 | NEW BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20150353559-A1 | NEW BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353559-A1 | NEW BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669268-B2 | Bicyclic derivatives | CCNY, BICRA, UQCRB | ENPP2 1716/4885DGAT2 3583/4885ATXN2 669/4885 |
| US-20180118741-A1 | NEW BICYCLIC DERIVATIVES | BICRA, CCNY, UQCRB | ENPP2 1981/4885DGAT2 3525/4885ATXN2 791/4885 |
| US-20150353559-A1 | NEW BICYCLIC DERIVATIVES | BICRA, CCNY, UQCRB | ENPP2 1981/4885DGAT2 3525/4885ATXN2 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.